Earnings Report: Here’s what to expect from Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

0
231

Earnings results for Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at 999 and remained the same over the past month at 999. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -0.84 and remained the same over the past month at -0.84 . none raised and none lowered their forecast.

Novus Therapeutics last released its earnings data on May 15th, 2020. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.31. Novus Therapeutics has generated ($1.20) earnings per share over the last year. Novus Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 18th, 2020 based off prior year’s report dates.

Analyst Opinion on Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

3 Wall Street analysts have issued ratings and price targets for Novus Therapeutics in the last 12 months. Their average twelve-month price target is $1.95, predicting that the stock has a possible upside of 373.07%. The high price target for NVUS is $3.25 and the low price target for NVUS is $0.60. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of “Hold.”

Novus Therapeutics has received a consensus rating of Hold. The company’s average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings. According to analysts’ consensus price target of $1.95, Novus Therapeutics has a forecasted upside of 373.1% from its current price of $0.41. Novus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

Novus Therapeutics does not currently pay a dividend. Novus Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

In the past three months, Novus Therapeutics insiders have not sold or bought any company stock. Only 5.60% of the stock of Novus Therapeutics is held by insiders. Only 33.52% of the stock of Novus Therapeutics is held by institutions.

Earnings and Valuation of Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS

Earnings for Novus Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.20) per share. The P/E ratio of Novus Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Novus Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Novus Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

More latest stories: here